Literature DB >> 3130094

Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro.

M S Runge1, C Bode, G R Matsueda, E Haber.   

Abstract

Tissue plasminogen activator (tPA) was covalently linked by disulfide bonds to a monoclonal antibody specific for the amino terminus of the beta chain of fibrin (antibody 59D8). The activity of the tPA-59D8 conjugate was compared with that of tPA, urokinase (UK), and a UK-59D8 conjugate. For lysis of fibrin monomer, tPA was 10 times as potent as UK, whereas both UK-59D8 and tPA-59D8 conjugates were 100 times as potent as UK and 10 times as potent as tPA. Conjugation of tPA or UK to antibody 59D8 produced a 3.2-4.5-fold enhancement in clot lysis in human plasma over that of the respective unconjugated plasminogen activator. However, the UK-59D8 conjugate was only as potent as tPA alone. Antibody-conjugated tPA or UK consumed less fibrinogen, alpha 2-antiplasmin, and plasminogen than did the unconjugated activators, at equipotent fibrinolytic concentrations. Antibody targeting thus appears to increase the concentration of tPA in the vicinity of a fibrin deposit, which thereby leads to enhanced fibrinolysis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3130094     DOI: 10.1021/bi00404a012

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

Review 1.  Advances in thrombolytic therapy.

Authors:  M Verstraete
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

2.  A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo.

Authors:  M S Runge; T Quertermous; P J Zavodny; T W Love; C Bode; M Freitag; S Y Shaw; P L Huang; C C Chou; D Mullins
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

Review 3.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

Review 4.  Binding of plasminogen activators to fibrin: characterization and pharmacological consequences.

Authors:  R Fears
Journal:  Biochem J       Date:  1989-07-15       Impact factor: 3.857

Review 5.  [Antibody mediated thrombolysis. A new therapeutic principle].

Authors:  C Bode; W Kübler
Journal:  Klin Wochenschr       Date:  1989-07-03

Review 6.  Cardiovascular therapies in the 1990s. An overview.

Authors:  R C Becker; J M Gore
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 7.  New strategies in the development of thrombolytic agents.

Authors:  H R Lijnen; D Collen
Journal:  Blut       Date:  1988-10

Review 8.  Thrombolytic therapy in acute myocardial infarction--selected recent developments.

Authors:  C Bode; T K Nordt; M S Runge
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

Review 9.  Thrombolytic agents in development.

Authors:  M Verstraete; H R Lijnen; D Collen
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

10.  A Novel and Potent Thrombolytic Fusion Protein Consisting of Anti-Insoluble Fibrin Antibody and Mutated Urokinase.

Authors:  Shingo Hanaoka; Shinji Saijou; Yasuhiro Matsumura
Journal:  Thromb Haemost       Date:  2021-06-15       Impact factor: 6.681

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.